Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Overweight, Obesity
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
25 Years to 60 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Chula Vista, California • Long Beach, California • San Diego, California + 7 more
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
30
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more
Conditions
Nasolabial Folds, Wrinkles
Interventions
TEOSYAL® RHA Ultra Deep
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Beverly Hills, California • Bradenton, Florida • Chapel Hill, North Carolina + 1 more
Conditions
Breast Cancer, Metastatic Cancer
Interventions
adenovirus-mediated human interleukin-12
Biological
Lead sponsor
Max Sung
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Newton, Kansas • Syracuse, New York • Ellensburg, Washington
Conditions
Ricin Poisoning
Interventions
RVEc
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Deterick, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine

NCT02620683
Conditions
Blood Levels of Buffered vs Non-buffered Lidocaine, Anesthetics, Local
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Local Anesthetics for Pain Reduction Prior to IV Line Placement

NCT01759459
Conditions
Pain, Local Anesthesia for Peripheral Intravenous Catheterization
Interventions
Lidocaine, Buffered Lidocaine, Bacteriostatic Normal Saline
Drug
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Low-Grade B-cell Lymphoma
Interventions
rhuFlt3L/CDX-301, Poly-ICLC
Drug
Lead sponsor
Joshua Brody
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Systemic Absorption of Lidocaine After Hematoma Block

NCT04359017
Conditions
Radius Fracture Distal, Hematoma, Lidocaine, Pediatrics
Interventions
Lidocaine 1% Injectable Solution
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Split Face Study of the Duration of Local Anesthetics

NCT05767749
Conditions
Anesthetics, Local
Interventions
lidocaine + epinephrine 1:100,000, Ropivacaine 0.5% Injectable Solution, Bupivacaine 0.5% Injectable Solution
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions
INO-4800, CELLECTRA® 2000, Placebo
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
Conditions
Friedreich Ataxia
Interventions
Nomlabofusp, Placebo
Drug
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chevy Chase, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine

NCT02747186
Conditions
Anesthesia
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA®4 for Midface Volume Deficiency

NCT05133739
Conditions
Cheek Augmentation, Correction of Age-related Midface Contour Deficiencies
Interventions
injection of RHA®4 in Midface, injection of Comparator Product in Midface
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Conditions
Cytomegalovirus Infections, HIV Infections, Vaccine
Interventions
CMV-MVA Triplex, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Conditions
HIV Infections
Interventions
AVX101, placebo
Biological · Other
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 2 more
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Conditions
HIV Infections
Interventions
DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease
Interventions
AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo
Biological · Other
Lead sponsor
Institute for Molecular Medicine
Other
Eligibility
65 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Boca Raton, Florida • Miami Lakes, Florida • Stuart, Florida + 3 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Conditions
Delirium, Sleep
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts